Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERBIRIX: Cetuximab, Irinotecan, and Capecitabine with Radiotherapy in Rectal Cancer
NCT00506844Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in rectal cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
cetuximab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00506844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506844.